Amgen Inc.
Pegylated carfilzomib compounds

Abstract:

The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I ##STR00001## wherein R.sup.1, R.sup.2, linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.